0000950170-25-059479.txt : 20250429 0000950170-25-059479.hdr.sgml : 20250429 20250428185616 ACCESSION NUMBER: 0000950170-25-059479 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250428 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 25882131 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 hrtx-20250428.htm 8-K 8-K
false000081803300008180332025-04-282025-04-28

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2025

Heron Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33221

94-2875566

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

100 Regency Forest Drive, Suite 300, Cary, NC

27518

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (858) 251-4400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

HRTX

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 28, 2025, Heron Therapeutics, Inc. (the “Company”) announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025 (the “Effective Date”).

Mr. Hensley, 42, joins the Company as Chief Operating Officer. Mr. Hensley brings extensive leadership and operational experience to Heron. Prior to joining Heron, Mr. Hensley held several senior leadership roles at Veloxis Pharmaceuticals, Inc. (“Veloxis”), a fully integrated specialty pharmaceutical company, including serving as Chief Executive Officer from 2021 to 2024, and Chief Operating Officer and Chief Commercial Officer from 2018 to 2021. Earlier in his career, Mr. Hensley held positions of increasing responsibility at Cornerstone Therapeutics and Chiesi USA. Mr. Hensley holds a Bachelor of Science in Biology and a Minor in Chemistry from the University of North Texas.

In connection with Mr. Hensley’s appointment, the Compensation Committee of the Board of Directors approved the following compensation arrangements for Mr. Hensley as of the Effective Date: (1) an annual base salary of $553,000; and (2) an annual target cash bonus of $276,500, which represents 50% of his annual base salary, although for 2025 the amount will be pro-rated for the portion of the year worked. Additionally, in connection with the commencement of Mr. Hensley’s employment, Mr. Hensley will receive inducement awards consisting of (i) a non-statutory stock option to purchase 500,000 shares of the Company’s common stock (the “Inducement Option”), (ii) 500,000 restricted stock units (the “Inducement RSUs”), and (iii) a non-statutory stock option to purchase up to 900,000 shares of the Company’s common stock based upon the achievement of certain common stock price goals (the “Inducement PSO”). The Inducement Option and Inducement PSO each have an exercise price based on the closing price per share as reported on the Nasdaq Capital Market as of the grant date, which is the Effective Date. The Inducement Option has a 10-year term with a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% vesting on a monthly basis over the next three years, subject to Mr. Hensley’s continuous service through each vesting date. The Inducement RSUs vest as to 25% of the shares subject to the Inducement RSUs on each of the first four anniversaries of the grant date, subject to Mr. Hensley’s continuous service through each such vesting date. The Inducement PSO has a 10-year term and vests as to a certain number of shares of the Company’s common stock upon achievement of certain stock price goals during Mr. Hensley’s employment with the Company and during the term of the Inducement PSO, subject to Mr. Hensley’s continuous service through each such vesting date. In accordance with Nasdaq Listing Rule 5635(c)(4), the inducement award grants were approved by the Company’s Compensation Committee and were made as a material inducement to Mr. Hensley entering into employment with the Company and outside of the Company’s Amended and Restated 2007 Equity Incentive Plan, as amended (the “2007 Plan”), but pursuant to the terms of the 2007 Plan as if the inducement awards were granted under the 2007 Plan.

In connection with his appointment, Mr. Hensley also entered into a Management Retention Agreement with the Company on the Effective Date (the “Retention Agreement”) on terms substantially similar to the Management Retention Agreements the Company has with the Company’s Executive Vice President, Chief Financial Officer and Executive Vice President, Chief Development Officer which are described in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 29, 2025. There are no arrangements or understandings between Mr. Hensley and any other persons pursuant to which he was selected as Chief Operating Officer. There are no family relationships between Mr. Hensley and any director or executive officer of the Company. There are no related party transactions between the Company and Mr. Hensley that would require disclosure under Item 404(a) of Regulation S-K.

A copy of the Press Release announcing the foregoing is furnished as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

 

Exhibit No.

Description

99.1

 

Press Release dated April 28, 2025

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Heron Therapeutics, Inc.

Date: April 28, 2025

/s/ Ira Duarte

Ira Duarte

Executive Vice President, Chief Financial Officer

 

 

 

 

 

 EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

CARY, Apr. 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry.

“I am excited to welcome Mark to Heron as our new Chief Operating Officer,” said Craig Collard, Chief Executive Officer of Heron. “Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficiency, effectiveness, and compliance as we advance our strategic priorities and execute on our growth initiatives.”

Mr. Hensley brings extensive leadership and operational experience to Heron. Prior to joining Heron, Mr. Hensley held several senior leadership roles at Veloxis Pharmaceuticals, Inc. (“Veloxis”), a fully integrated specialty pharmaceutical company, including serving as Chief Executive Officer from 2021 to 2024, and Chief Operating Officer and Chief Commercial Officer from 2018 to 2021. Earlier in his career, Mr. Hensley held positions of increasing responsibility at Cornerstone Therapeutics and Chiesi USA. Mr. Hensley holds a Bachelor of Science in Biology and a Minor in Chemistry from the University of North Texas.

In connection with the commencement of Mr. Hensley’s employment, Mr. Hensley will receive inducement awards consisting of (i) a non-statutory stock option to purchase 500,000 shares of Heron common stock (“Inducement Option”), (ii) 500,000 restricted stock units (“Inducement RSUs”), and (iii) a non-statutory stock option to purchase up to 900,000 shares of Heron common stock based upon the achievement of certain common stock price goals (“Inducement PSO”). The Inducement Option and Inducement PSO each have an exercise price based on the closing price per share as reported on the Nasdaq Capital Market as of April 28, 2025, the effective date of the grants and the start date of Mr. Hensley’s employment with Heron. The Inducement Option has a 10-year term with a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% vesting on a monthly basis over the next three years, subject to Mr. Hensley’s continuous service through each vesting date. The Inducement RSUs vest as to 25% of the shares subject to the Inducement RSUs on each of the first four anniversaries of the grant date, subject to Mr. Hensley’s continuous service through each such vesting date. The Inducement PSO has a 10-year term and vests as to a certain number of shares of the Company’s common stock upon achievement of certain stock price goals during Mr. Hensley’s employment with the Company and during the term of the Inducement PSO, subject to Mr. Hensley’s continuous service through each such vesting date. In accordance with Nasdaq Listing Rule 5635(c)(4), the inducement award grants were approved by the Compensation Committee of the Board of Directors and were made as a material inducement to Mr. Hensley entering into employment with Heron.

About Heron Therapeutics, Inc.

 

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

 

 

 

 

 

Forward-looking Statements

 

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors.” Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400

 

 

 

 

 EX-101.SCH 3 hrtx-20250428.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Entity Addresses, Address Type [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation State or Country Code Entity Incorporation, State or Country Code Document Information [Table] Entity Central Index Key Entity Central Index Key Entity Address, State or Province Entity Address, State or Province Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line One Amendment Flag Amendment Flag Entity Address, City or Town Entity Address, City or Town Document Type Document Type Title of 12b Security Title of 12(b) Security Address Type [Domain] Former Address [Member] Former Address [Member] Soliciting Material Soliciting Material Entity Address, Address Line Two Entity Address, Address Line Two Document Period End Date Document Period End Date Trading Symbol Trading Symbol Pre Commencement Tender Offer Pre-commencement Tender Offer Security Exchange Name Security Exchange Name Written Communications Written Communications Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Securities Act File Number Entity Tax Identification Number Entity Tax Identification Number City Area Code City Area Code Local Phone Number Local Phone Number Document Information [Line Items] XML 5 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information
Apr. 28, 2025
Document Information [Line Items]  
Entity Registrant Name Heron Therapeutics, Inc.
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0000818033
Document Type 8-K
Document Period End Date Apr. 28, 2025
Entity Incorporation State or Country Code DE
Entity File Number 001-33221
Entity Tax Identification Number 94-2875566
Entity Address, Address Line One 100 Regency Forest Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Cary
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27518
City Area Code (858)
Local Phone Number 251-4400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Title of 12b Security Common Stock, par value $0.01 per share
Trading Symbol HRTX
Entity Emerging Growth Company false
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports hrtx-20250428.htm hrtx-20250428.xsd http://xbrl.sec.gov/dei/2024 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hrtx-20250428.htm": { "nsprefix": "hrtx", "nsuri": "http://www.herontx.com/20250428", "dts": { "inline": { "local": [ "hrtx-20250428.htm" ] }, "schema": { "local": [ "hrtx-20250428.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_44b9588d-14ee-48e5-92a6-8ac8eeb43ee9", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrtx-20250428.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_44b9588d-14ee-48e5-92a6-8ac8eeb43ee9", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrtx-20250428.htm", "first": true, "unique": true } } }, "tag": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "terseLabel": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r6", "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12b Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.herontx.com/20250428/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-25-059479-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-25-059479-xbrl.zip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end XML 14 hrtx-20250428_htm.xml IDEA: XBRL DOCUMENT 0000818033 2025-04-28 2025-04-28 false 0000818033 8-K 2025-04-28 Heron Therapeutics, Inc. DE 001-33221 94-2875566 100 Regency Forest Drive Suite 300 Cary NC 27518 (858) 251-4400 false false false false Common Stock, par value $0.01 per share HRTX NASDAQ false